MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 20, 2020 | $200,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Nov 24, 2020 | $230,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R./S.1: Tax Cuts and Jobs Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER New | — |
| PETER SLONE | — |
Tariff (miscellaneous tariff bills) TAR
USTR Section 301 proposed tariffs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER New | — |
| PETER SLONE | — |
Medicare/Medicaid MMM
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| DAMON SHELBY PORTER New | — |
| PETER SLONE | — |
Health Issues HCR
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. H.R. 6637, the Health Equity and Accountability Act (HEAA), H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act, S.4264 - U.S. MADE Act of 2020, H.R. 6880 - The Buy American Medical Supplies Act, H.R. 6930 - MADE in America Act, H.R. 3 Lower Drug Costs Now Act of 2019, H.R.1845 - ALERT Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| DAMON SHELBY PORTER New | — |
| PETER SLONE | — |
Pharmacy PHA
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act. H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| DAMON SHELBY PORTER New | — |
| PETER SLONE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.